MXPA06013632A - 4-heteroaril-pirimidinas 2-sustituidas utiles para el tratamiento de trastornos proliferativos. - Google Patents
4-heteroaril-pirimidinas 2-sustituidas utiles para el tratamiento de trastornos proliferativos.Info
- Publication number
- MXPA06013632A MXPA06013632A MXPA06013632A MXPA06013632A MXPA06013632A MX PA06013632 A MXPA06013632 A MX PA06013632A MX PA06013632 A MXPA06013632 A MX PA06013632A MX PA06013632 A MXPA06013632 A MX PA06013632A MX PA06013632 A MXPA06013632 A MX PA06013632A
- Authority
- MX
- Mexico
- Prior art keywords
- methyl
- thiazol
- pyrimidin
- phenyl
- amino
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims description 205
- 238000011282 treatment Methods 0.000 claims abstract description 57
- 102000001253 Protein Kinase Human genes 0.000 claims abstract description 22
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 108060006633 protein kinase Proteins 0.000 claims abstract description 22
- 230000002062 proliferating effect Effects 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 230000003612 virological effect Effects 0.000 claims abstract description 7
- -1 R9-alkyl Chemical group 0.000 claims description 616
- 125000000217 alkyl group Chemical group 0.000 claims description 147
- 125000003118 aryl group Chemical group 0.000 claims description 85
- 125000004463 2,4-dimethyl-thiazol-5-yl group Chemical group CC=1SC(=C(N1)C)* 0.000 claims description 59
- 229910052736 halogen Inorganic materials 0.000 claims description 51
- 150000002367 halogens Chemical class 0.000 claims description 50
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 40
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 39
- 150000003839 salts Chemical class 0.000 claims description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 38
- 125000003545 alkoxy group Chemical group 0.000 claims description 36
- 208000035475 disorder Diseases 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical group NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 32
- 125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 32
- 125000001424 substituent group Chemical group 0.000 claims description 27
- 238000003556 assay Methods 0.000 claims description 26
- 239000003814 drug Substances 0.000 claims description 25
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 24
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 22
- 230000003381 solubilizing effect Effects 0.000 claims description 21
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 20
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 20
- 229940124530 sulfonamide Drugs 0.000 claims description 20
- 108090000433 Aurora kinases Proteins 0.000 claims description 19
- 102000003989 Aurora kinases Human genes 0.000 claims description 19
- 125000002723 alicyclic group Polymers 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 19
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 18
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Chemical group CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 16
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Chemical group CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical compound [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Substances OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 125000004122 cyclic group Chemical group 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 125000001931 aliphatic group Chemical group 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 claims description 11
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 claims description 11
- 229910052799 carbon Inorganic materials 0.000 claims description 11
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims description 10
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims description 10
- 150000004292 cyclic ethers Chemical class 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 229910052760 oxygen Inorganic materials 0.000 claims description 10
- 229910052717 sulfur Inorganic materials 0.000 claims description 10
- WMYBWPZOKYUYHQ-UHFFFAOYSA-N 1-[4-[3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 WMYBWPZOKYUYHQ-UHFFFAOYSA-N 0.000 claims description 9
- KKZLCEABFUFJHM-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-methylsulfonylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C=CC=2)S(C)(=O)=O)=N1 KKZLCEABFUFJHM-UHFFFAOYSA-N 0.000 claims description 9
- YNNLNAPIIVWREC-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-piperazin-1-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C=CC=2)N2CCNCC2)=N1 YNNLNAPIIVWREC-UHFFFAOYSA-N 0.000 claims description 9
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 claims description 9
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 206010012601 diabetes mellitus Diseases 0.000 claims description 9
- MKZYCKFHJVCYGG-UHFFFAOYSA-N n-[[3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]methyl]-1,1,1-trifluoromethanesulfonamide Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(CNS(=O)(=O)C(F)(F)F)C=CC=3)N=CC=2)=C1C MKZYCKFHJVCYGG-UHFFFAOYSA-N 0.000 claims description 9
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 8
- 102100031463 Serine/threonine-protein kinase PLK1 Human genes 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 8
- 125000001033 ether group Chemical group 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 108010056274 polo-like kinase 1 Proteins 0.000 claims description 8
- DOBOZMUVNVYNLF-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-methyl-4-piperidin-1-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C)C(N3CCCCC3)=CC=2)=N1 DOBOZMUVNVYNLF-UHFFFAOYSA-N 0.000 claims description 7
- GGVWWYJGNSVOOQ-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(4-piperidin-1-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCCCC2)=N1 GGVWWYJGNSVOOQ-UHFFFAOYSA-N 0.000 claims description 7
- MSLDXLIUSOSHSA-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(4-thiomorpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCSCC2)=N1 MSLDXLIUSOSHSA-UHFFFAOYSA-N 0.000 claims description 7
- GMRHSZXJSJNDHZ-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[3-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CN3CCOCC3)C=CC=2)=N1 GMRHSZXJSJNDHZ-UHFFFAOYSA-N 0.000 claims description 7
- SXGSWCDDSRJDTO-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[4-methoxy-3-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine Chemical compound C1=C(CN2CCOCC2)C(OC)=CC=C1NC(N=1)=NC=CC=1C=1SC(C)=NC=1C SXGSWCDDSRJDTO-UHFFFAOYSA-N 0.000 claims description 7
- YGXOMEYMYMUEEV-UHFFFAOYSA-N 4-methyl-5-[2-(3-methyl-4-piperidin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C)C(N4CCCCC4)=CC=3)N=CC=2)=C1C YGXOMEYMYMUEEV-UHFFFAOYSA-N 0.000 claims description 7
- WIRNEQAIBUAVLP-UHFFFAOYSA-N 4-methyl-5-[2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCNCC3)N=CC=2)=C1C WIRNEQAIBUAVLP-UHFFFAOYSA-N 0.000 claims description 7
- XGOQGRONEKZZQT-UHFFFAOYSA-N 4-methyl-5-[2-(4-piperidin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCCCC3)N=CC=2)=C1C XGOQGRONEKZZQT-UHFFFAOYSA-N 0.000 claims description 7
- AJVAMKMZGVKFMK-UHFFFAOYSA-N 4-methyl-5-[2-(4-thiomorpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCSCC3)N=CC=2)=C1C AJVAMKMZGVKFMK-UHFFFAOYSA-N 0.000 claims description 7
- 102100026810 Cyclin-dependent kinase 7 Human genes 0.000 claims description 7
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 7
- 101000911952 Homo sapiens Cyclin-dependent kinase 7 Proteins 0.000 claims description 7
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims description 7
- HSLPGZVMVMTNLG-UHFFFAOYSA-N [5-[2-(3-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-yl]methanol Chemical compound C=1C=C(N2CCOCC2)C(OC)=CC=1NC(N=1)=NC=CC=1C=1SC(CO)=NC=1C HSLPGZVMVMTNLG-UHFFFAOYSA-N 0.000 claims description 7
- DDXXFYMQASOCAE-UHFFFAOYSA-N n-(2-methoxyethyl)-4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound S1C(NCCOC)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 DDXXFYMQASOCAE-UHFFFAOYSA-N 0.000 claims description 7
- QWDFRAOGDXXNAM-UHFFFAOYSA-N n-(3-methoxy-4-morpholin-4-ylphenyl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound C=1C=C(N2CCOCC2)C(OC)=CC=1NC(N=1)=NC=CC=1C(=C(N=1)C)SC=1C1=CC=CN=C1 QWDFRAOGDXXNAM-UHFFFAOYSA-N 0.000 claims description 7
- ZSIXBFIBEOQNSX-UHFFFAOYSA-N n-[[3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]methyl]-1,1,1-trifluoromethanesulfonamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CNS(=O)(=O)C(F)(F)F)C=CC=2)=N1 ZSIXBFIBEOQNSX-UHFFFAOYSA-N 0.000 claims description 7
- GUFQYCOGYHRMAZ-UHFFFAOYSA-N n-ethyl-4-methyl-5-[2-(4-piperazin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound S1C(NCC)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCNCC2)=N1 GUFQYCOGYHRMAZ-UHFFFAOYSA-N 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 201000004384 Alopecia Diseases 0.000 claims description 6
- 241000713772 Human immunodeficiency virus 1 Species 0.000 claims description 6
- 150000001409 amidines Chemical group 0.000 claims description 6
- 150000001719 carbohydrate derivatives Chemical class 0.000 claims description 6
- 239000003085 diluting agent Substances 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- NMUICMGXTPBDAK-UHFFFAOYSA-N n,4-dimethyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-n-pyridin-3-yl-1,3-thiazol-2-amine Chemical compound C=1C=CN=CC=1N(C)C(S1)=NC(C)=C1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 NMUICMGXTPBDAK-UHFFFAOYSA-N 0.000 claims description 6
- OJNPFEPSIXIFKN-UHFFFAOYSA-N n-[4-(2,6-dimethylmorpholin-4-yl)phenyl]-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound C1C(C)OC(C)CN1C(C=C1)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 OJNPFEPSIXIFKN-UHFFFAOYSA-N 0.000 claims description 6
- YJJKMZKHSQMMTM-UHFFFAOYSA-N 4-[4-methyl-2-(thiophen-2-ylsulfonylmethyl)-1,3-thiazol-5-yl]-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C(C)N=C1CS(=O)(=O)C1=CC=CS1 YJJKMZKHSQMMTM-UHFFFAOYSA-N 0.000 claims description 5
- QOBGKWWRAPVAHZ-UHFFFAOYSA-N 4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-2-(morpholin-4-ylmethyl)phenol Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CN3CCOCC3)C(O)=CC=2)=N1 QOBGKWWRAPVAHZ-UHFFFAOYSA-N 0.000 claims description 5
- FESYXBVCBFMFGM-UHFFFAOYSA-N 4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCOC)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 FESYXBVCBFMFGM-UHFFFAOYSA-N 0.000 claims description 5
- BMKHMLOSFHGSCW-UHFFFAOYSA-N 4-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCOC)=CC=C1NC1=NC=CC(C2=C(N=C(N)S2)C)=N1 BMKHMLOSFHGSCW-UHFFFAOYSA-N 0.000 claims description 5
- OQWUAZIPUCLTLQ-UHFFFAOYSA-N 4-methyl-5-[2-(4-methyl-3-morpholin-4-ylsulfonylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C(C)=CC=3)S(=O)(=O)N3CCOCC3)N=CC=2)=C1C OQWUAZIPUCLTLQ-UHFFFAOYSA-N 0.000 claims description 5
- YOLKAZLNKSERGQ-UHFFFAOYSA-N 5-[2-(3-methoxy-4-morpholin-4-ylanilino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C=1C=C(N2CCOCC2)C(OC)=CC=1NC(N=1)=NC=CC=1C=1SC(N)=NC=1C YOLKAZLNKSERGQ-UHFFFAOYSA-N 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 101100037762 Caenorhabditis elegans rnh-2 gene Proteins 0.000 claims description 5
- 101100134929 Gallus gallus COR9 gene Proteins 0.000 claims description 5
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 5
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 5
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- ZYHPYQACTSXUDE-UHFFFAOYSA-N [3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-5-(hydroxymethyl)phenyl]methanol Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CO)C=C(CO)C=2)=N1 ZYHPYQACTSXUDE-UHFFFAOYSA-N 0.000 claims description 5
- 231100000360 alopecia Toxicity 0.000 claims description 5
- 150000003857 carboxamides Chemical class 0.000 claims description 5
- HVESLTJNPMAQNR-UHFFFAOYSA-N cyclopropyl-[4-[4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]methanone Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCN(CC2)C(=O)C2CC2)=N1 HVESLTJNPMAQNR-UHFFFAOYSA-N 0.000 claims description 5
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 claims description 5
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 5
- BFVATTPOPABDOP-UHFFFAOYSA-N n-ethyl-n,4-dimethyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound S1C(N(C)CC)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCOCC2)=N1 BFVATTPOPABDOP-UHFFFAOYSA-N 0.000 claims description 5
- 229920000570 polyether Polymers 0.000 claims description 5
- 150000003456 sulfonamides Chemical class 0.000 claims description 5
- 150000003457 sulfones Chemical class 0.000 claims description 5
- 150000003462 sulfoxides Chemical class 0.000 claims description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 5
- 239000003981 vehicle Substances 0.000 claims description 5
- 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 claims description 4
- 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 claims description 4
- 208000005189 Embolism Diseases 0.000 claims description 4
- 208000031886 HIV Infections Diseases 0.000 claims description 4
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 4
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 4
- 241000701024 Human betaherpesvirus 5 Species 0.000 claims description 4
- 229910004727 OSO3H Inorganic materials 0.000 claims description 4
- 229910018828 PO3H2 Inorganic materials 0.000 claims description 4
- LJKQHMFUGPKGDU-UHFFFAOYSA-N [4-methyl-5-[2-(3-methyl-4-piperidin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-yl]methanol Chemical compound N1=C(CO)SC(C=2N=C(NC=3C=C(C)C(N4CCCCC4)=CC=3)N=CC=2)=C1C LJKQHMFUGPKGDU-UHFFFAOYSA-N 0.000 claims description 4
- GQSACQZGAVTUSA-UHFFFAOYSA-N [4-methyl-5-[2-(4-piperidin-1-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-yl]methanol Chemical compound N1=C(CO)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCCCC3)N=CC=2)=C1C GQSACQZGAVTUSA-UHFFFAOYSA-N 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 238000012875 competitive assay Methods 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 4
- ZBYYPNTVDDUJTC-UHFFFAOYSA-N 1-[4-[4-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=CC(C2=C(N=C(N)S2)C)=N1 ZBYYPNTVDDUJTC-UHFFFAOYSA-N 0.000 claims description 3
- LKLWKLSHKBYATH-UHFFFAOYSA-N 1-[4-[4-[[4-[2-[benzyl(methyl)amino]-4-methyl-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound N=1C(C)=C(C=2N=C(NC=3C=CC(=CC=3)N3CCN(CC3)C(C)=O)N=CC=2)SC=1N(C)CC1=CC=CC=C1 LKLWKLSHKBYATH-UHFFFAOYSA-N 0.000 claims description 3
- LZCVCEPISTVVDN-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]acetamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC(=O)CC=2C=CC(Cl)=CC=2)=N1 LZCVCEPISTVVDN-UHFFFAOYSA-N 0.000 claims description 3
- WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 claims description 3
- LKQVGJAARVKDHU-UHFFFAOYSA-N 3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C=CC=2)S(=O)(=O)NCCO)=N1 LKQVGJAARVKDHU-UHFFFAOYSA-N 0.000 claims description 3
- PZFKBISGJKEYSB-UHFFFAOYSA-N 3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 PZFKBISGJKEYSB-UHFFFAOYSA-N 0.000 claims description 3
- YNUAGHMOARFTOW-UHFFFAOYSA-N 3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C=CC=3)S(=O)(=O)NCCO)N=CC=2)=C1C YNUAGHMOARFTOW-UHFFFAOYSA-N 0.000 claims description 3
- JBOXLGMWEAVPBK-UHFFFAOYSA-N 3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 JBOXLGMWEAVPBK-UHFFFAOYSA-N 0.000 claims description 3
- WZGHCPBEOCOZJD-UHFFFAOYSA-N 3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-ethylbenzenesulfonamide Chemical compound CCNS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 WZGHCPBEOCOZJD-UHFFFAOYSA-N 0.000 claims description 3
- JZFGTIBTHDQTDA-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(2-methyl-4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C(=CC(=CC=2)N2CCOCC2)C)=N1 JZFGTIBTHDQTDA-UHFFFAOYSA-N 0.000 claims description 3
- WOHBHEXSHHPQIV-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 WOHBHEXSHHPQIV-UHFFFAOYSA-N 0.000 claims description 3
- BYOPENLWBFNNNS-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-methoxy-4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound C=1C=C(N2CCOCC2)C(OC)=CC=1NC(N=1)=NC=CC=1C=1SC(C)=NC=1C BYOPENLWBFNNNS-UHFFFAOYSA-N 0.000 claims description 3
- FNEBWEFHBCRADV-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-methyl-4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C)C(N3CCOCC3)=CC=2)=N1 FNEBWEFHBCRADV-UHFFFAOYSA-N 0.000 claims description 3
- ZSPVVQZVCCMOGB-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(3-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C=CC=2)N2CCOCC2)=N1 ZSPVVQZVCCMOGB-UHFFFAOYSA-N 0.000 claims description 3
- IPIICOPOXASIMM-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(4-methoxy-2-methylphenyl)pyrimidin-2-amine Chemical compound CC1=CC(OC)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 IPIICOPOXASIMM-UHFFFAOYSA-N 0.000 claims description 3
- OHUBJYNRZKXNJM-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(4-pyrrolidin-1-ylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)N2CCCC2)=N1 OHUBJYNRZKXNJM-UHFFFAOYSA-N 0.000 claims description 3
- PVMQBNNUCWAOAU-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(5-methoxy-2-methylphenyl)pyrimidin-2-amine Chemical compound COC1=CC=C(C)C(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 PVMQBNNUCWAOAU-UHFFFAOYSA-N 0.000 claims description 3
- IKIMLXMGMUHBRO-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-[4-(morpholin-4-ylmethyl)phenyl]pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(CN3CCOCC3)=CC=2)=N1 IKIMLXMGMUHBRO-UHFFFAOYSA-N 0.000 claims description 3
- NVHPLXZBCLDQRP-UHFFFAOYSA-N 4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)-n-(3,4,5-trimethoxyphenyl)pyrimidin-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(S2)C=2C=NC=CC=2)C)=C1 NVHPLXZBCLDQRP-UHFFFAOYSA-N 0.000 claims description 3
- BHEMMLNBOSWXPM-UHFFFAOYSA-N 4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 BHEMMLNBOSWXPM-UHFFFAOYSA-N 0.000 claims description 3
- VHUXLQLYXBRQHF-UHFFFAOYSA-N 4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)-n-(4-pyrrolidin-1-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCCC1 VHUXLQLYXBRQHF-UHFFFAOYSA-N 0.000 claims description 3
- DWJZDTVDXRAQGH-UHFFFAOYSA-N 4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)-n-(4-thiomorpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCSCC1 DWJZDTVDXRAQGH-UHFFFAOYSA-N 0.000 claims description 3
- BSVFPDRDFRUTIW-UHFFFAOYSA-N 4-(4-methyl-2-thiophen-2-yl-1,3-thiazol-5-yl)-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2SC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 BSVFPDRDFRUTIW-UHFFFAOYSA-N 0.000 claims description 3
- VSHSQQGEVOCBET-UHFFFAOYSA-N 4-[2-(2,4-dimethylphenyl)-4-methyl-1,3-thiazol-5-yl]-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C(=CC(C)=CC=2)C)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 VSHSQQGEVOCBET-UHFFFAOYSA-N 0.000 claims description 3
- XNPYGAZXDQCZNI-UHFFFAOYSA-N 4-[2-(2-ethylpyridin-4-yl)-4-methyl-1,3-thiazol-5-yl]-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound C1=NC(CC)=CC(C=2SC(=C(C)N=2)C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C1 XNPYGAZXDQCZNI-UHFFFAOYSA-N 0.000 claims description 3
- DXTVDZJPGQYZII-UHFFFAOYSA-N 4-[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC(C)=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 DXTVDZJPGQYZII-UHFFFAOYSA-N 0.000 claims description 3
- GZGKJZGRKPYOCM-UHFFFAOYSA-N 4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCCO)=N1 GZGKJZGRKPYOCM-UHFFFAOYSA-N 0.000 claims description 3
- ZJIUFQPTWAZXSU-UHFFFAOYSA-N 4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-ethylbenzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCC)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 ZJIUFQPTWAZXSU-UHFFFAOYSA-N 0.000 claims description 3
- NZVIANFXUONPFE-UHFFFAOYSA-N 4-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-(2-hydroxyethyl)benzenesulfonamide Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)S(=O)(=O)NCCO)N=CC=2)=C1C NZVIANFXUONPFE-UHFFFAOYSA-N 0.000 claims description 3
- RQDGPMPATRISII-UHFFFAOYSA-N 4-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-benzylbenzenesulfonamide Chemical compound N1=C(N)SC(C=2N=C(NC=3C=CC(=CC=3)S(=O)(=O)NCC=3C=CC=CC=3)N=CC=2)=C1C RQDGPMPATRISII-UHFFFAOYSA-N 0.000 claims description 3
- XVDMWYFAQWBXJM-UHFFFAOYSA-N 4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound S1C(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C(C)N=C1NCCC1=CC=CC=C1 XVDMWYFAQWBXJM-UHFFFAOYSA-N 0.000 claims description 3
- WDHOTEXWBPFBKY-UHFFFAOYSA-N 4-methyl-n-(2-phenylethyl)-5-[2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(NCCC=3C=CC=CC=3)S2)C)=C1 WDHOTEXWBPFBKY-UHFFFAOYSA-N 0.000 claims description 3
- LRWFZAGCWBXQDC-UHFFFAOYSA-N 4-n-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-1-n-methyl-2-(trifluoromethyl)benzene-1,4-diamine Chemical compound C1=C(C(F)(F)F)C(NC)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 LRWFZAGCWBXQDC-UHFFFAOYSA-N 0.000 claims description 3
- KAFZBYLUGVPMRJ-UHFFFAOYSA-N 5-[2-(1,3-benzodioxol-5-ylamino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C4OCOC4=CC=3)N=CC=2)=C1C KAFZBYLUGVPMRJ-UHFFFAOYSA-N 0.000 claims description 3
- SIADTHKIHZVNGE-UHFFFAOYSA-N 5-[2-(3,5-dimethoxyanilino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 SIADTHKIHZVNGE-UHFFFAOYSA-N 0.000 claims description 3
- JGWRJJYQNXXYBW-UHFFFAOYSA-N 5-[2-(4-methoxy-3-methylanilino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-amine Chemical compound C1=C(C)C(OC)=CC=C1NC1=NC=CC(C2=C(N=C(N)S2)C)=N1 JGWRJJYQNXXYBW-UHFFFAOYSA-N 0.000 claims description 3
- VCOZZNBECSZJEM-UHFFFAOYSA-N 5-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-2-morpholin-4-ylbenzamide Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C(N4CCOCC4)=CC=3)C(N)=O)N=CC=2)=C1C VCOZZNBECSZJEM-UHFFFAOYSA-N 0.000 claims description 3
- 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 claims description 3
- 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 claims description 3
- 102000019058 Glycogen Synthase Kinase 3 beta Human genes 0.000 claims description 3
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 claims description 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 claims description 3
- 229910006069 SO3H Inorganic materials 0.000 claims description 3
- YUFSSZBXBVYWOJ-UHFFFAOYSA-N [4-methyl-5-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-yl]methanol Chemical compound N1=C(CO)SC(C=2N=C(NC=3C=CC(=CC=3)N3CCOCC3)N=CC=2)=C1C YUFSSZBXBVYWOJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 3
- 230000008859 change Effects 0.000 claims description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 claims description 3
- SOHYJMKRQNHQNU-UHFFFAOYSA-N n-(1,3-benzodioxol-5-yl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C=2N=C(NC=3C=C4OCOC4=CC=3)N=CC=2)=C(C)N=C1C1=CC=CN=C1 SOHYJMKRQNHQNU-UHFFFAOYSA-N 0.000 claims description 3
- TVSHKODCQBKHAE-UHFFFAOYSA-N n-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C=2N=C(NC=3C=C4OCCOC4=CC=3)N=CC=2)=C(C)N=C1C1=CC=CN=C1 TVSHKODCQBKHAE-UHFFFAOYSA-N 0.000 claims description 3
- LGWYQQLCZSKFSS-UHFFFAOYSA-N n-(3,5-dichloro-4-morpholin-4-ylphenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(Cl)C(N3CCOCC3)=C(Cl)C=2)=N1 LGWYQQLCZSKFSS-UHFFFAOYSA-N 0.000 claims description 3
- RIDZMYFVSVJBGX-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 RIDZMYFVSVJBGX-UHFFFAOYSA-N 0.000 claims description 3
- AHYZNCKAQMWADI-UHFFFAOYSA-N n-(3-chloro-4-morpholin-4-ylphenyl)-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(Cl)C(N3CCOCC3)=CC=2)=N1 AHYZNCKAQMWADI-UHFFFAOYSA-N 0.000 claims description 3
- OTDXZCJDGOEYPJ-UHFFFAOYSA-N n-(3-chloro-4-morpholin-4-ylphenyl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1Cl)=CC=C1N1CCOCC1 OTDXZCJDGOEYPJ-UHFFFAOYSA-N 0.000 claims description 3
- ARYAOOHLSUTMRN-UHFFFAOYSA-N n-(3-methyl-4-piperidin-1-ylphenyl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1C)=CC=C1N1CCCCC1 ARYAOOHLSUTMRN-UHFFFAOYSA-N 0.000 claims description 3
- APCHKTVBUYRQTQ-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC1=CC=CC(CN)=C1 APCHKTVBUYRQTQ-UHFFFAOYSA-N 0.000 claims description 3
- JVCBOOGOEWNDPV-UHFFFAOYSA-N n-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 JVCBOOGOEWNDPV-UHFFFAOYSA-N 0.000 claims description 3
- QPDLOBKNDHXKJT-UHFFFAOYSA-N n-[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]-2-(4-nitrophenyl)acetamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC(=O)CC=2C=CC(=CC=2)[N+]([O-])=O)=N1 QPDLOBKNDHXKJT-UHFFFAOYSA-N 0.000 claims description 3
- KYFWXTZMBHZNDA-UHFFFAOYSA-N n-benzyl-4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=CC(=CC=2)S(=O)(=O)NCC=2C=CC=CC=2)=N1 KYFWXTZMBHZNDA-UHFFFAOYSA-N 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 3
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 3
- JVINBTZUMCFCHW-UHFFFAOYSA-N 5-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)pyrimidin-4-yl]-4-methyl-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound S1C(C=2N=C(NC=3C=C4OCCOC4=CC=3)N=CC=2)=C(C)N=C1NCCC1=CC=CC=C1 JVINBTZUMCFCHW-UHFFFAOYSA-N 0.000 claims description 2
- 208000020925 Bipolar disease Diseases 0.000 claims description 2
- 108010025468 Cyclin-Dependent Kinase 6 Proteins 0.000 claims description 2
- 102100036329 Cyclin-dependent kinase 3 Human genes 0.000 claims description 2
- 102100026804 Cyclin-dependent kinase 6 Human genes 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 101000715946 Homo sapiens Cyclin-dependent kinase 3 Proteins 0.000 claims description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 208000012902 Nervous system disease Diseases 0.000 claims description 2
- 229910006074 SO2NH2 Inorganic materials 0.000 claims description 2
- 150000001412 amines Chemical group 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000004692 haloalkylcarbonyl group Chemical group 0.000 claims description 2
- YFKPOENKJUXEQS-UHFFFAOYSA-N n-(3,5-dichloro-4-morpholin-4-ylphenyl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=NC=CC=2)SC=1C(N=1)=CC=NC=1NC(C=C1Cl)=CC(Cl)=C1N1CCOCC1 YFKPOENKJUXEQS-UHFFFAOYSA-N 0.000 claims description 2
- YHKCLWVQANLILS-UHFFFAOYSA-N n-[[3-[[4-[2-(2-ethylpyridin-4-yl)-4-methyl-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]methyl]acetamide Chemical compound C1=NC(CC)=CC(C=2SC(=C(C)N=2)C=2N=C(NC=3C=C(CNC(C)=O)C=CC=3)N=CC=2)=C1 YHKCLWVQANLILS-UHFFFAOYSA-N 0.000 claims description 2
- PALCECFPEDXKDZ-UHFFFAOYSA-N n-[[3-[[4-[4-methyl-2-(6-methylpyridin-3-yl)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(S2)C=2C=NC(C)=CC=2)C)=C1 PALCECFPEDXKDZ-UHFFFAOYSA-N 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims 4
- WWDBCOFSUSWIRI-UHFFFAOYSA-N 1-[4-[4-[[4-[4-methyl-2-(2-phenylethylamino)-1,3-thiazol-5-yl]pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1NC1=NC=CC(C2=C(N=C(NCCC=3C=CC=CC=3)S2)C)=N1 WWDBCOFSUSWIRI-UHFFFAOYSA-N 0.000 claims 2
- WGZSYSREPOMDEP-UHFFFAOYSA-N 4-[4-methyl-2-(4-morpholin-4-ylphenyl)-1,3-thiazol-5-yl]-n-(4-morpholin-4-ylphenyl)pyrimidin-2-amine Chemical compound CC=1N=C(C=2C=CC(=CC=2)N2CCOCC2)SC=1C(N=1)=CC=NC=1NC(C=C1)=CC=C1N1CCOCC1 WGZSYSREPOMDEP-UHFFFAOYSA-N 0.000 claims 2
- XDDJYXJYNJNLEL-UHFFFAOYSA-N 4-methyl-5-[2-(3,4,5-trimethoxyanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound COC1=C(OC)C(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 XDDJYXJYNJNLEL-UHFFFAOYSA-N 0.000 claims 2
- LUPMNXFZYLXVMR-UHFFFAOYSA-N 4-methyl-5-[2-(3-morpholin-4-ylsulfonylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C=CC=3)S(=O)(=O)N3CCOCC3)N=CC=2)=C1C LUPMNXFZYLXVMR-UHFFFAOYSA-N 0.000 claims 2
- POUZVNZXMVCXCI-UHFFFAOYSA-N 5-[2-(3,5-dimethoxyanilino)pyrimidin-4-yl]-4-methyl-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(NCCC=3C=CC=CC=3)S2)C)=C1 POUZVNZXMVCXCI-UHFFFAOYSA-N 0.000 claims 2
- LTPYFLPMAQYNQC-UHFFFAOYSA-N 5-[2-[4-(4-benzylpiperazin-1-yl)anilino]pyrimidin-4-yl]-4-methyl-n-(2-phenylethyl)-1,3-thiazol-2-amine Chemical compound S1C(C=2N=C(NC=3C=CC(=CC=3)N3CCN(CC=4C=CC=CC=4)CC3)N=CC=2)=C(C)N=C1NCCC1=CC=CC=C1 LTPYFLPMAQYNQC-UHFFFAOYSA-N 0.000 claims 2
- LACIISPXRNIXKD-UHFFFAOYSA-N 5-[2-[4-(4-benzylpiperazin-1-yl)anilino]pyrimidin-4-yl]-4-methyl-n-phenyl-1,3-thiazol-2-amine Chemical compound S1C(C=2N=C(NC=3C=CC(=CC=3)N3CCN(CC=4C=CC=CC=4)CC3)N=CC=2)=C(C)N=C1NC1=CC=CC=C1 LACIISPXRNIXKD-UHFFFAOYSA-N 0.000 claims 2
- 108090000749 Aurora kinase B Proteins 0.000 claims 2
- 101001052849 Homo sapiens Tyrosine-protein kinase Fer Proteins 0.000 claims 2
- 102100024537 Tyrosine-protein kinase Fer Human genes 0.000 claims 2
- XOAYPVYCLLYFCT-UHFFFAOYSA-N n-(3,5-dimethoxyphenyl)-4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound COC1=CC(OC)=CC(NC=2N=C(C=CN=2)C2=C(N=C(S2)C=2C=NC=CC=2)C)=C1 XOAYPVYCLLYFCT-UHFFFAOYSA-N 0.000 claims 2
- HSSIQNYMGPHASH-UHFFFAOYSA-N n-[3-(aminomethyl)phenyl]-4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CN)C=CC=2)=N1 HSSIQNYMGPHASH-UHFFFAOYSA-N 0.000 claims 2
- RTNMUUJWHBQRAH-UHFFFAOYSA-N n-[3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]sulfonylacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 RTNMUUJWHBQRAH-UHFFFAOYSA-N 0.000 claims 2
- ZNKZJVFVQPPQOC-UHFFFAOYSA-N n-[[3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]methyl]pyridine-2-carboxamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(CNC(=O)C=3N=CC=CC=3)C=CC=2)=N1 ZNKZJVFVQPPQOC-UHFFFAOYSA-N 0.000 claims 2
- RMCCONIRBZIDTH-UHFFFAOYSA-N 2-(2-methylprop-2-enoyloxy)ethyl 1,3-dioxo-2-benzofuran-5-carboxylate Chemical compound CC(=C)C(=O)OCCOC(=O)C1=CC=C2C(=O)OC(=O)C2=C1 RMCCONIRBZIDTH-UHFFFAOYSA-N 0.000 claims 1
- 102100032306 Aurora kinase B Human genes 0.000 claims 1
- 102000004228 Aurora kinase B Human genes 0.000 claims 1
- 102000006835 Lamins Human genes 0.000 claims 1
- 108010047294 Lamins Proteins 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 241001139947 Mida Species 0.000 claims 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 210000005053 lamin Anatomy 0.000 claims 1
- 230000000414 obstructive effect Effects 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 614
- 239000007787 solid Substances 0.000 description 223
- 238000005160 1H NMR spectroscopy Methods 0.000 description 221
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 217
- 238000004007 reversed phase HPLC Methods 0.000 description 217
- 238000004458 analytical method Methods 0.000 description 216
- 238000000132 electrospray ionisation Methods 0.000 description 193
- 238000006243 chemical reaction Methods 0.000 description 173
- 210000004027 cell Anatomy 0.000 description 41
- 235000002639 sodium chloride Nutrition 0.000 description 40
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 38
- KZHPWLCGQFOOPP-UHFFFAOYSA-N 3-(dimethylamino)-1-[4-methyl-2-(methylamino)-1,3-thiazol-5-yl]prop-2-en-1-one Chemical compound CNC1=NC(C)=C(C(=O)C=CN(C)C)S1 KZHPWLCGQFOOPP-UHFFFAOYSA-N 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- 229910052739 hydrogen Inorganic materials 0.000 description 17
- 108091000080 Phosphotransferase Proteins 0.000 description 16
- 230000027455 binding Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 102000020233 phosphotransferase Human genes 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- 238000009833 condensation Methods 0.000 description 15
- 230000005494 condensation Effects 0.000 description 15
- ZVZJREQBRCRGLM-UHFFFAOYSA-N 2-(4-morpholin-4-ylphenyl)guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCOCC1 ZVZJREQBRCRGLM-UHFFFAOYSA-N 0.000 description 14
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 14
- 239000003446 ligand Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 239000000758 substrate Substances 0.000 description 14
- PVMAWJZIHWQALU-UHFFFAOYSA-N n'-[5-[3-(dimethylamino)prop-2-enoyl]-4-methyl-1,3-thiazol-2-yl]-n,n-dimethylmethanimidamide Chemical compound CN(C)C=CC(=O)C=1SC(N=CN(C)C)=NC=1C PVMAWJZIHWQALU-UHFFFAOYSA-N 0.000 description 13
- 125000000714 pyrimidinyl group Chemical group 0.000 description 13
- 102000001267 GSK3 Human genes 0.000 description 12
- 108060006662 GSK3 Proteins 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 12
- NFVJNJQRWPQVOA-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-2-[3-(4-ethyl-5-ethylsulfanyl-1,2,4-triazol-3-yl)piperidin-1-yl]acetamide Chemical compound CCN1C(SCC)=NN=C1C1CN(CC(=O)NC=2C(=CC=C(C=2)C(F)(F)F)Cl)CCC1 NFVJNJQRWPQVOA-UHFFFAOYSA-N 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229940024606 amino acid Drugs 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 230000001419 dependent effect Effects 0.000 description 9
- MSILSEAASITEGZ-UHFFFAOYSA-N 2-[4-(4-acetylpiperazin-1-yl)phenyl]guanidine Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(NC(N)=N)C=C1 MSILSEAASITEGZ-UHFFFAOYSA-N 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- 108010001483 Glycogen Synthase Proteins 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- CPRRHERYRRXBRZ-SRVKXCTJSA-N methyl n-[(2s)-1-[[(2s)-1-hydroxy-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound COC(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CO)C[C@@H]1CCNC1=O CPRRHERYRRXBRZ-SRVKXCTJSA-N 0.000 description 8
- 230000004048 modification Effects 0.000 description 8
- 238000012986 modification Methods 0.000 description 8
- WKHNZFJILJVAAV-UHFFFAOYSA-N n-[[3-(diaminomethylideneamino)phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(NC(N)=N)=C1 WKHNZFJILJVAAV-UHFFFAOYSA-N 0.000 description 8
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 7
- 229910019142 PO4 Inorganic materials 0.000 description 7
- 230000004913 activation Effects 0.000 description 7
- 230000022131 cell cycle Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 7
- 239000010452 phosphate Substances 0.000 description 7
- 239000002243 precursor Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- CDBWVYYYKYLWIW-UHFFFAOYSA-N 2-(3,5-dimethoxyphenyl)guanidine Chemical compound COC1=CC(NC(N)=N)=CC(OC)=C1 CDBWVYYYKYLWIW-UHFFFAOYSA-N 0.000 description 6
- VPPCGWOYRDHGNH-UHFFFAOYSA-N 2-[3-(methylsulfamoyl)phenyl]guanidine Chemical compound CNS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 VPPCGWOYRDHGNH-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N Lactic Acid Natural products CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 102000029749 Microtubule Human genes 0.000 description 6
- 108091022875 Microtubule Proteins 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 6
- 102100026209 Serine/threonine-protein kinase PLK3 Human genes 0.000 description 6
- 241000700605 Viruses Species 0.000 description 6
- 230000001028 anti-proliverative effect Effects 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 210000004688 microtubule Anatomy 0.000 description 6
- 108010026424 tau Proteins Proteins 0.000 description 6
- IOMPAACMNZLPEP-UHFFFAOYSA-N 2-(3-methoxy-4-morpholin-4-ylphenyl)guanidine Chemical compound COC1=CC(NC(N)=N)=CC=C1N1CCOCC1 IOMPAACMNZLPEP-UHFFFAOYSA-N 0.000 description 5
- UINCWWJLWMQTLS-UHFFFAOYSA-N 2-(3-methyl-4-piperidin-1-ylphenyl)guanidine Chemical compound CC1=CC(NC(N)=N)=CC=C1N1CCCCC1 UINCWWJLWMQTLS-UHFFFAOYSA-N 0.000 description 5
- WGUXAYNUYPJTSO-UHFFFAOYSA-N 2-[4-(4-benzylpiperazin-1-yl)phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCN(CC=2C=CC=CC=2)CC1 WGUXAYNUYPJTSO-UHFFFAOYSA-N 0.000 description 5
- 229920002527 Glycogen Polymers 0.000 description 5
- 101000691614 Homo sapiens Serine/threonine-protein kinase PLK3 Proteins 0.000 description 5
- 102100034343 Integrase Human genes 0.000 description 5
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000003793 centrosome Anatomy 0.000 description 5
- 229940096919 glycogen Drugs 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000000394 mitotic effect Effects 0.000 description 5
- 235000011007 phosphoric acid Nutrition 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 238000006366 phosphorylation reaction Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 239000011541 reaction mixture Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000013498 tau Proteins Human genes 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- MZLGFUWJJQGNSE-UHFFFAOYSA-N 2-(3-chloro-4-morpholin-4-ylphenyl)guanidine Chemical compound ClC1=CC(NC(=N)N)=CC=C1N1CCOCC1 MZLGFUWJJQGNSE-UHFFFAOYSA-N 0.000 description 4
- YCCABNVKAUHJLG-UHFFFAOYSA-N 2-(4-methoxy-3-methylphenyl)guanidine Chemical compound COC1=CC=C(NC(N)=N)C=C1C YCCABNVKAUHJLG-UHFFFAOYSA-N 0.000 description 4
- XMQMFNBUHWVOKP-UHFFFAOYSA-N 2-(4-thiomorpholin-4-ylphenyl)guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCSCC1 XMQMFNBUHWVOKP-UHFFFAOYSA-N 0.000 description 4
- MRORJIPQRHCPGA-UHFFFAOYSA-N 2-[4-(2-hydroxyethylsulfamoyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=C(S(=O)(=O)NCCO)C=C1 MRORJIPQRHCPGA-UHFFFAOYSA-N 0.000 description 4
- XVBCPLDWUWBCRM-UHFFFAOYSA-N 2-[4-(benzylsulfamoyl)phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1S(=O)(=O)NCC1=CC=CC=C1 XVBCPLDWUWBCRM-UHFFFAOYSA-N 0.000 description 4
- KOTKBGAWYCEQCW-UHFFFAOYSA-N 5-(diaminomethylideneamino)-2-morpholin-4-ylbenzamide Chemical compound NC(=O)C1=CC(NC(=N)N)=CC=C1N1CCOCC1 KOTKBGAWYCEQCW-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 4
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 4
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Natural products OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 4
- 101000729945 Homo sapiens Serine/threonine-protein kinase PLK2 Proteins 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 4
- 230000027311 M phase Effects 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Natural products OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 102100031462 Serine/threonine-protein kinase PLK2 Human genes 0.000 description 4
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 4
- KKEYFWRCBNTPAC-UHFFFAOYSA-N Terephthalic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C=C1 KKEYFWRCBNTPAC-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- 238000000021 kinase assay Methods 0.000 description 4
- 108020001756 ligand binding domains Proteins 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 150000002772 monosaccharides Chemical class 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 208000015122 neurodegenerative disease Diseases 0.000 description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-N picolinic acid Chemical compound OC(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 229940002612 prodrug Drugs 0.000 description 4
- 239000000651 prodrug Substances 0.000 description 4
- 230000031877 prophase Effects 0.000 description 4
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- SOBSYGGSAKHFRZ-UHFFFAOYSA-N 2-(2,3-dihydro-1,4-benzodioxin-6-yl)guanidine Chemical compound O1CCOC2=CC(NC(=N)N)=CC=C21 SOBSYGGSAKHFRZ-UHFFFAOYSA-N 0.000 description 3
- OHFPDMMPVYDFLQ-UHFFFAOYSA-N 2-(3,5-dichloro-4-morpholin-4-ylphenyl)guanidine Chemical compound ClC1=CC(NC(=N)N)=CC(Cl)=C1N1CCOCC1 OHFPDMMPVYDFLQ-UHFFFAOYSA-N 0.000 description 3
- YXYITUUKFWVBKZ-UHFFFAOYSA-N 2-(4-piperidin-1-ylphenyl)guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCCCC1 YXYITUUKFWVBKZ-UHFFFAOYSA-N 0.000 description 3
- KCLOVBATQJVWRN-UHFFFAOYSA-N 2-[3-(2-hydroxyethylsulfamoyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC(S(=O)(=O)NCCO)=C1 KCLOVBATQJVWRN-UHFFFAOYSA-N 0.000 description 3
- PNMOZNZKWITVPZ-UHFFFAOYSA-N 2-[3-(2-methoxyethylsulfamoyl)phenyl]guanidine Chemical compound COCCNS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 PNMOZNZKWITVPZ-UHFFFAOYSA-N 0.000 description 3
- RWOJNAKNHZUALN-UHFFFAOYSA-N 2-[4-(4-methylpiperazin-1-yl)phenyl]guanidine Chemical compound C1CN(C)CCN1C1=CC=C(NC(N)=N)C=C1 RWOJNAKNHZUALN-UHFFFAOYSA-N 0.000 description 3
- JAHLCZRCFROZJE-UHFFFAOYSA-N 3-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(C)S2)C)=C1 JAHLCZRCFROZJE-UHFFFAOYSA-N 0.000 description 3
- MPLSNQAHULTSPR-UHFFFAOYSA-N 3-[[4-(2-amino-4-methyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-n-methylbenzenesulfonamide Chemical compound CNS(=O)(=O)C1=CC=CC(NC=2N=C(C=CN=2)C2=C(N=C(N)S2)C)=C1 MPLSNQAHULTSPR-UHFFFAOYSA-N 0.000 description 3
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical compound C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 108060000903 Beta-catenin Proteins 0.000 description 3
- 102000015735 Beta-catenin Human genes 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 102000002427 Cyclin B Human genes 0.000 description 3
- 108010068150 Cyclin B Proteins 0.000 description 3
- 230000004543 DNA replication Effects 0.000 description 3
- 230000010337 G2 phase Effects 0.000 description 3
- 102000038624 GSKs Human genes 0.000 description 3
- 108091007911 GSKs Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 3
- 150000001735 carboxylic acids Chemical class 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 235000019439 ethyl acetate Nutrition 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 238000013537 high throughput screening Methods 0.000 description 3
- 210000005260 human cell Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000011278 mitosis Effects 0.000 description 3
- WDSUCLZQISBFNC-UHFFFAOYSA-N n-(diaminomethylidene)-2-(4-methoxyphenyl)acetamide Chemical compound COC1=CC=C(CC(=O)NC(N)=N)C=C1 WDSUCLZQISBFNC-UHFFFAOYSA-N 0.000 description 3
- FOXLIQYQZPXEKB-UHFFFAOYSA-N n-[[4-(diaminomethylideneamino)phenyl]methyl]acetamide;nitric acid Chemical compound O[N+]([O-])=O.CC(=O)NCC1=CC=C(N=C(N)N)C=C1 FOXLIQYQZPXEKB-UHFFFAOYSA-N 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 229960005190 phenylalanine Drugs 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 210000002027 skeletal muscle Anatomy 0.000 description 3
- 239000012453 solvate Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000565 sulfonamide group Chemical group 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 2
- NPKYNQPMKHIDCY-GGXBSVTOSA-N (2z)-2-[(4z)-4-(5-butyl-5-methylfuran-2-ylidene)-3,5-dioxooxolan-2-ylidene]acetic acid Chemical compound C1=CC(CCCC)(C)O\C1=C/1C(=O)C(=C/C(O)=O)/OC\1=O NPKYNQPMKHIDCY-GGXBSVTOSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 2
- OZINHCFSCQEUPW-UHFFFAOYSA-N 2-(1,3-benzodioxol-5-yl)guanidine Chemical compound NC(N)=NC1=CC=C2OCOC2=C1 OZINHCFSCQEUPW-UHFFFAOYSA-N 0.000 description 2
- DXUWATABALHSNY-UHFFFAOYSA-N 2-(3,4,5-trimethoxyphenyl)guanidine Chemical compound COC1=CC(NC(N)=N)=CC(OC)=C1OC DXUWATABALHSNY-UHFFFAOYSA-N 0.000 description 2
- VCNPGEBJIJVOBQ-UHFFFAOYSA-N 2-(3-methyl-4-morpholin-4-ylphenyl)guanidine Chemical compound CC1=CC(NC(N)=N)=CC=C1N1CCOCC1 VCNPGEBJIJVOBQ-UHFFFAOYSA-N 0.000 description 2
- STNOHBVCPOGOJS-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(diaminomethylidene)acetamide Chemical compound NC(=N)NC(=O)CC1=CC=C(Cl)C=C1 STNOHBVCPOGOJS-UHFFFAOYSA-N 0.000 description 2
- YUGWZGNJSXXXIY-UHFFFAOYSA-N 2-(4-methoxy-2-methylphenyl)guanidine Chemical compound COC1=CC=C(NC(N)=N)C(C)=C1 YUGWZGNJSXXXIY-UHFFFAOYSA-N 0.000 description 2
- WLBFFOGQDRWGCE-UHFFFAOYSA-N 2-(4-methyl-3-morpholin-4-ylsulfonylphenyl)guanidine Chemical compound CC1=CC=C(NC(N)=N)C=C1S(=O)(=O)N1CCOCC1 WLBFFOGQDRWGCE-UHFFFAOYSA-N 0.000 description 2
- IKPCNXZHIZDFSG-UHFFFAOYSA-N 2-(4-methylsulfonylphenyl)guanidine Chemical compound CS(=O)(=O)C1=CC=C(NC(N)=N)C=C1 IKPCNXZHIZDFSG-UHFFFAOYSA-N 0.000 description 2
- UJPBFJLWUHYVOH-UHFFFAOYSA-N 2-(4-pyrrolidin-1-ylphenyl)guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCCC1 UJPBFJLWUHYVOH-UHFFFAOYSA-N 0.000 description 2
- FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 2
- OTGRGCVWGQFRIZ-UHFFFAOYSA-N 2-[3-(4-acetylpiperazin-1-yl)phenyl]guanidine Chemical compound C1CN(C(=O)C)CCN1C1=CC=CC(NC(N)=N)=C1 OTGRGCVWGQFRIZ-UHFFFAOYSA-N 0.000 description 2
- DUIWKHFDNMBFJL-UHFFFAOYSA-N 2-[3-(ethylsulfamoyl)phenyl]guanidine Chemical compound CCNS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 DUIWKHFDNMBFJL-UHFFFAOYSA-N 0.000 description 2
- RWHGYJJWNIBORS-UHFFFAOYSA-N 2-[4-(2,6-dimethylmorpholin-4-yl)phenyl]guanidine Chemical compound C1C(C)OC(C)CN1C1=CC=C(NC(N)=N)C=C1 RWHGYJJWNIBORS-UHFFFAOYSA-N 0.000 description 2
- MWIYIRFJQACQKB-UHFFFAOYSA-N 2-[4-(morpholin-4-ylmethyl)phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1CN1CCOCC1 MWIYIRFJQACQKB-UHFFFAOYSA-N 0.000 description 2
- WIGDGIGALMYEBW-LLINQDLYSA-N 2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-methylpentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]acetic acid Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)NCC(O)=O WIGDGIGALMYEBW-LLINQDLYSA-N 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 2
- QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-UHFFFAOYSA-N Aspartic acid Chemical compound OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000004000 Aurora Kinase A Human genes 0.000 description 2
- 108090000461 Aurora Kinase A Proteins 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 230000012746 DNA damage checkpoint Effects 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 201000011240 Frontotemporal dementia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Natural products OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 101000621390 Homo sapiens Wee1-like protein kinase Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 2
- 231100000002 MTT assay Toxicity 0.000 description 2
- 238000000134 MTT assay Methods 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 102100023037 Wee1-like protein kinase Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000031016 anaphase Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 239000012131 assay buffer Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 238000007385 chemical modification Methods 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 2
- 230000021953 cytokinesis Effects 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 238000002784 cytotoxicity assay Methods 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 230000030609 dephosphorylation Effects 0.000 description 2
- 238000006209 dephosphorylation reaction Methods 0.000 description 2
- 150000001991 dicarboxylic acids Chemical class 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 230000003779 hair growth Effects 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 150000004679 hydroxides Chemical class 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- NPKYNQPMKHIDCY-UHFFFAOYSA-N italicic acid Natural products C1=CC(CCCC)(C)OC1=C1C(=O)C(=CC(O)=O)OC1=O NPKYNQPMKHIDCY-UHFFFAOYSA-N 0.000 description 2
- 108010082683 kemptide Proteins 0.000 description 2
- 238000000464 low-speed centrifugation Methods 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- XPZCFLHFDRKTNN-UHFFFAOYSA-N n-(diaminomethylidene)-2-(4-nitrophenyl)acetamide Chemical compound NC(=N)NC(=O)CC1=CC=C([N+]([O-])=O)C=C1 XPZCFLHFDRKTNN-UHFFFAOYSA-N 0.000 description 2
- XAAAOZKUYZXREG-UHFFFAOYSA-N n-[3-(diaminomethylideneamino)phenyl]sulfonylacetamide Chemical compound CC(=O)NS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 XAAAOZKUYZXREG-UHFFFAOYSA-N 0.000 description 2
- AHUIPHOADUNSRL-UHFFFAOYSA-N n-[[4-(diaminomethylideneamino)phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=C(NC(N)=N)C=C1 AHUIPHOADUNSRL-UHFFFAOYSA-N 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 230000009223 neuronal apoptosis Effects 0.000 description 2
- XDTAXLLLQKDXDL-UHFFFAOYSA-N nitric acid;2-(3,4,5-trimethoxyphenyl)guanidine Chemical compound O[N+]([O-])=O.COC1=CC(N=C(N)N)=CC(OC)=C1OC XDTAXLLLQKDXDL-UHFFFAOYSA-N 0.000 description 2
- 210000000633 nuclear envelope Anatomy 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002972 pentoses Chemical class 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 239000008024 pharmaceutical diluent Substances 0.000 description 2
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 150000004043 trisaccharides Chemical class 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- ZDRLKQLULCHOAJ-SECBINFHSA-N (2S)-2-amino-2,3,3-trifluoro-3-(4-hydroxyphenyl)propanoic acid Chemical compound FC([C@](N)(C(=O)O)F)(C1=CC=C(C=C1)O)F ZDRLKQLULCHOAJ-SECBINFHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WNNNWFKQCKFSDK-BYPYZUCNSA-N (2s)-2-aminopent-4-enoic acid Chemical compound OC(=O)[C@@H](N)CC=C WNNNWFKQCKFSDK-BYPYZUCNSA-N 0.000 description 1
- GTVVZTAFGPQSPC-QMMMGPOBSA-N (2s)-2-azaniumyl-3-(4-nitrophenyl)propanoate Chemical compound OC(=O)[C@@H](N)CC1=CC=C([N+]([O-])=O)C=C1 GTVVZTAFGPQSPC-QMMMGPOBSA-N 0.000 description 1
- DLZXLCHQWOZGSE-UHFFFAOYSA-N (3-nitrophenyl)methylazanium;chloride Chemical compound Cl.NCC1=CC=CC([N+]([O-])=O)=C1 DLZXLCHQWOZGSE-UHFFFAOYSA-N 0.000 description 1
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 1
- ITMCNFXXXOJIMK-UHFFFAOYSA-N 1-[2-(hydroxymethyl)-4-methyl-1,3-thiazol-5-yl]ethanone Chemical compound CC(=O)C=1SC(CO)=NC=1C ITMCNFXXXOJIMK-UHFFFAOYSA-N 0.000 description 1
- ZEVQFEXNVZZJNM-UHFFFAOYSA-N 1-[4-(3-nitrophenyl)piperazin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCN1C1=CC=CC([N+]([O-])=O)=C1 ZEVQFEXNVZZJNM-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FQSOFDYKCFUBFE-UHFFFAOYSA-N 2-(2-methyl-4-morpholin-4-ylphenyl)guanidine Chemical compound C1=C(NC(N)=N)C(C)=CC(N2CCOCC2)=C1 FQSOFDYKCFUBFE-UHFFFAOYSA-N 0.000 description 1
- PDLJJKTUWIOCOJ-UHFFFAOYSA-N 2-(3-bromo-4-methylphenyl)guanidine;nitric acid Chemical compound O[N+]([O-])=O.CC1=CC=C(N=C(N)N)C=C1Br PDLJJKTUWIOCOJ-UHFFFAOYSA-N 0.000 description 1
- KNWNQGNSSXGMGL-UHFFFAOYSA-N 2-(3-bromophenyl)guanidine;nitric acid Chemical compound O[N+]([O-])=O.NC(N)=NC1=CC=CC(Br)=C1 KNWNQGNSSXGMGL-UHFFFAOYSA-N 0.000 description 1
- CHRXRXUMSZHQLE-UHFFFAOYSA-N 2-(3-methoxy-4-piperidin-1-ylphenyl)guanidine Chemical compound COC1=CC(NC(N)=N)=CC=C1N1CCCCC1 CHRXRXUMSZHQLE-UHFFFAOYSA-N 0.000 description 1
- UFKHGUCOQPLRQV-UHFFFAOYSA-N 2-(3-methylsulfonylphenyl)guanidine Chemical compound CS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 UFKHGUCOQPLRQV-UHFFFAOYSA-N 0.000 description 1
- ZKDPCYZCXFCNEG-UHFFFAOYSA-N 2-(3-morpholin-4-ylphenyl)guanidine Chemical compound NC(=N)NC1=CC=CC(N2CCOCC2)=C1 ZKDPCYZCXFCNEG-UHFFFAOYSA-N 0.000 description 1
- LJHRJVGGFYZSMF-UHFFFAOYSA-N 2-(3-morpholin-4-ylsulfonylphenyl)guanidine Chemical compound NC(=N)NC1=CC=CC(S(=O)(=O)N2CCOCC2)=C1 LJHRJVGGFYZSMF-UHFFFAOYSA-N 0.000 description 1
- JBXHYJJFLGCHBQ-UHFFFAOYSA-N 2-(3-sulfamoylphenyl)guanidine Chemical compound NC(=N)NC1=CC=CC(S(N)(=O)=O)=C1 JBXHYJJFLGCHBQ-UHFFFAOYSA-N 0.000 description 1
- KVYVGOKRQRECNI-UHFFFAOYSA-N 2-(4-methyl-3-morpholin-4-ylphenyl)guanidine Chemical compound CC1=CC=C(NC(N)=N)C=C1N1CCOCC1 KVYVGOKRQRECNI-UHFFFAOYSA-N 0.000 description 1
- OJDGRVUTPGQSDV-UHFFFAOYSA-N 2-(4-methyl-3-nitrophenyl)guanidine;nitric acid Chemical compound O[N+]([O-])=O.CC1=CC=C(N=C(N)N)C=C1[N+]([O-])=O OJDGRVUTPGQSDV-UHFFFAOYSA-N 0.000 description 1
- NNLYYGCCOGDKFD-UHFFFAOYSA-N 2-(5-methoxy-2-methylphenyl)guanidine Chemical compound COC1=CC=C(C)C(NC(N)=N)=C1 NNLYYGCCOGDKFD-UHFFFAOYSA-N 0.000 description 1
- IRXOVUKSPWZRJB-UHFFFAOYSA-N 2-(pyridin-3-ylmethyl)guanidine Chemical compound NC(=N)NCC1=CC=CN=C1 IRXOVUKSPWZRJB-UHFFFAOYSA-N 0.000 description 1
- GKZZQMYPQYJXIP-UHFFFAOYSA-N 2-[3,5-bis(hydroxymethyl)phenyl]guanidine;nitric acid Chemical compound O[N+]([O-])=O.NC(N)=NC1=CC(CO)=CC(CO)=C1 GKZZQMYPQYJXIP-UHFFFAOYSA-N 0.000 description 1
- WULVAFIGHJBILA-UHFFFAOYSA-N 2-[3-(aminomethyl)phenyl]guanidine Chemical compound NCC1=CC=CC(NC(N)=N)=C1 WULVAFIGHJBILA-UHFFFAOYSA-N 0.000 description 1
- UJNLIEKHTCGLPI-UHFFFAOYSA-N 2-[3-(benzylsulfamoyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC(S(=O)(=O)NCC=2C=CC=CC=2)=C1 UJNLIEKHTCGLPI-UHFFFAOYSA-N 0.000 description 1
- BPMRYGYRCGILKB-UHFFFAOYSA-N 2-[3-(morpholin-4-ylmethyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=CC(CN2CCOCC2)=C1 BPMRYGYRCGILKB-UHFFFAOYSA-N 0.000 description 1
- VGSVPIGOECJUCP-UHFFFAOYSA-N 2-[3-[(1-hydroxy-2-methylpropan-2-yl)sulfamoyl]phenyl]guanidine Chemical compound OCC(C)(C)NS(=O)(=O)C1=CC=CC(NC(N)=N)=C1 VGSVPIGOECJUCP-UHFFFAOYSA-N 0.000 description 1
- UYLNWRIYVUGCIR-UHFFFAOYSA-N 2-[4-(2-methoxyethylsulfamoyl)phenyl]guanidine Chemical compound COCCNS(=O)(=O)C1=CC=C(NC(N)=N)C=C1 UYLNWRIYVUGCIR-UHFFFAOYSA-N 0.000 description 1
- NSSSNINCMLWHGZ-UHFFFAOYSA-N 2-[4-(diethylsulfamoyl)phenyl]guanidine Chemical compound CCN(CC)S(=O)(=O)C1=CC=C(NC(N)=N)C=C1 NSSSNINCMLWHGZ-UHFFFAOYSA-N 0.000 description 1
- NAAHSJLHESEXLU-UHFFFAOYSA-N 2-[4-(dimethylamino)phenyl]guanidine Chemical compound CN(C)C1=CC=C(N=C(N)N)C=C1 NAAHSJLHESEXLU-UHFFFAOYSA-N 0.000 description 1
- VLHDIVFBUHFJBQ-UHFFFAOYSA-N 2-[4-(ethylsulfamoyl)phenyl]guanidine Chemical compound CCNS(=O)(=O)C1=CC=C(NC(N)=N)C=C1 VLHDIVFBUHFJBQ-UHFFFAOYSA-N 0.000 description 1
- GTVYVSRKJUHPDO-UHFFFAOYSA-N 2-[4-(methylamino)-3-(trifluoromethyl)phenyl]guanidine Chemical compound CNC1=CC=C(NC(N)=N)C=C1C(F)(F)F GTVYVSRKJUHPDO-UHFFFAOYSA-N 0.000 description 1
- CWZJSJIMRAHRFO-UHFFFAOYSA-N 2-[4-[4-(cyclopropanecarbonyl)piperazin-1-yl]phenyl]guanidine Chemical compound C1=CC(NC(=N)N)=CC=C1N1CCN(C(=O)C2CC2)CC1 CWZJSJIMRAHRFO-UHFFFAOYSA-N 0.000 description 1
- YRKCXSSEDMMDGD-UHFFFAOYSA-N 2-[4-[4-(diaminomethylideneamino)phenyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C1=CC=C(NC(N)=N)C=C1 YRKCXSSEDMMDGD-UHFFFAOYSA-N 0.000 description 1
- BUJKBZKGTVBPGO-UHFFFAOYSA-N 2-[4-[4-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]phenyl]piperazin-1-yl]-n-propan-2-ylacetamide Chemical compound C1CN(CC(=O)NC(C)C)CCN1C(C=C1)=CC=C1NC1=NC=CC(C2=C(N=C(C)S2)C)=N1 BUJKBZKGTVBPGO-UHFFFAOYSA-N 0.000 description 1
- XSBWGOIJZNXYEU-UHFFFAOYSA-N 2-[4-hydroxy-3-(morpholin-4-ylmethyl)phenyl]guanidine Chemical compound NC(=N)NC1=CC=C(O)C(CN2CCOCC2)=C1 XSBWGOIJZNXYEU-UHFFFAOYSA-N 0.000 description 1
- QTNWIBQLURUPJO-UHFFFAOYSA-N 2-hydroxyethanethioamide Chemical group NC(=S)CO QTNWIBQLURUPJO-UHFFFAOYSA-N 0.000 description 1
- ASUDFOJKTJLAIK-UHFFFAOYSA-N 2-methoxyethanamine Chemical compound COCCN ASUDFOJKTJLAIK-UHFFFAOYSA-N 0.000 description 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 description 1
- VLRGXXKFHVJQOL-UHFFFAOYSA-N 3-chloropentane-2,4-dione Chemical compound CC(=O)C(Cl)C(C)=O VLRGXXKFHVJQOL-UHFFFAOYSA-N 0.000 description 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 1
- MBNPJRQKQLLRIS-UHFFFAOYSA-N 3-methylsulfonylaniline Chemical compound CS(=O)(=O)C1=CC=CC(N)=C1 MBNPJRQKQLLRIS-UHFFFAOYSA-N 0.000 description 1
- 102100037263 3-phosphoinositide-dependent protein kinase 1 Human genes 0.000 description 1
- QYBVKPOTSCJIIR-UHFFFAOYSA-N 4-(2,4-dimethyl-1,3-thiazol-5-yl)-n-(4-methyl-3-morpholin-4-ylsulfonylphenyl)pyrimidin-2-amine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C(C)=CC=2)S(=O)(=O)N2CCOCC2)=N1 QYBVKPOTSCJIIR-UHFFFAOYSA-N 0.000 description 1
- CTFDMGIBHFQWKB-UHFFFAOYSA-N 4-(2,4-dimethyl-thiazol-5-yl)-pyrimidin-2-ylamine Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(N)=N1 CTFDMGIBHFQWKB-UHFFFAOYSA-N 0.000 description 1
- LDTXZWHXMSJEEP-UHFFFAOYSA-N 4-amino-n-(2-methoxyethyl)benzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=C(N)C=C1 LDTXZWHXMSJEEP-UHFFFAOYSA-N 0.000 description 1
- 229940090248 4-hydroxybenzoic acid Drugs 0.000 description 1
- AVIVQSJULPCODN-UHFFFAOYSA-N 4-methyl-5-[2-(3-methyl-4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2N=C(NC=3C=C(C)C(N4CCOCC4)=CC=3)N=CC=2)=C1C AVIVQSJULPCODN-UHFFFAOYSA-N 0.000 description 1
- JXRGUPLJCCDGKG-UHFFFAOYSA-N 4-nitrobenzenesulfonyl chloride Chemical compound [O-][N+](=O)C1=CC=C(S(Cl)(=O)=O)C=C1 JXRGUPLJCCDGKG-UHFFFAOYSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- XDAQPAFEUOICHR-UHFFFAOYSA-N 5-[[4-(2,4-dimethyl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]-2-morpholin-4-ylbenzamide Chemical compound S1C(C)=NC(C)=C1C1=CC=NC(NC=2C=C(C(N3CCOCC3)=CC=2)C(N)=O)=N1 XDAQPAFEUOICHR-UHFFFAOYSA-N 0.000 description 1
- FJCTYKTVKYGSAR-UHFFFAOYSA-N 6-[2-(3,5-dimethyl-1-phenylpyrazol-4-yl)ethyl]-3-(phenylsulfanylmethyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1CCC(SC1=NN=2)=NN1C=2CSC1=CC=CC=C1 FJCTYKTVKYGSAR-UHFFFAOYSA-N 0.000 description 1
- USQCUKQZXOWUDF-YWZLYKJASA-N 6-chloro-n-[(3s)-1-[(2s)-1-(4-methyl-5-oxo-1,4-diazepan-1-yl)-1-oxopropan-2-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide Chemical compound O=C([C@@H](N1C([C@@H](NS(=O)(=O)C=2C=C3C=CC(Cl)=CC3=CC=2)CC1)=O)C)N1CCN(C)C(=O)CC1 USQCUKQZXOWUDF-YWZLYKJASA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- XDOLZJYETYVRKV-UHFFFAOYSA-N 7-Aminoheptanoic acid Chemical compound NCCCCCCC(O)=O XDOLZJYETYVRKV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 1
- 102000043139 CK2 family Human genes 0.000 description 1
- 108091054872 CK2 family Proteins 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-NJFSPNSNSA-N Carbon-14 Chemical compound [14C] OKTJSMMVPCPJKN-NJFSPNSNSA-N 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 101710118321 Casein kinase I isoform alpha Proteins 0.000 description 1
- 108091060290 Chromatid Proteins 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 108050006400 Cyclin Proteins 0.000 description 1
- 102000016736 Cyclin Human genes 0.000 description 1
- 102000002554 Cyclin A Human genes 0.000 description 1
- 108010068192 Cyclin A Proteins 0.000 description 1
- 102000003910 Cyclin D Human genes 0.000 description 1
- 108090000259 Cyclin D Proteins 0.000 description 1
- 102000003909 Cyclin E Human genes 0.000 description 1
- 108090000257 Cyclin E Proteins 0.000 description 1
- 102000002495 Cyclin H Human genes 0.000 description 1
- 102000002435 Cyclin T Human genes 0.000 description 1
- 108010068106 Cyclin T Proteins 0.000 description 1
- 102100036876 Cyclin-K Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 241000255601 Drosophila melanogaster Species 0.000 description 1
- 101001004391 Drosophila melanogaster Protein jim lovell Proteins 0.000 description 1
- 101100373143 Drosophila melanogaster Wnt5 gene Proteins 0.000 description 1
- 102100031480 Dual specificity mitogen-activated protein kinase kinase 1 Human genes 0.000 description 1
- 102100040862 Dual specificity protein kinase CLK1 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102100030011 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical class FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 102100035108 High affinity nerve growth factor receptor Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000600756 Homo sapiens 3-phosphoinositide-dependent protein kinase 1 Proteins 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 101000713120 Homo sapiens Cyclin-H Proteins 0.000 description 1
- 101000713127 Homo sapiens Cyclin-K Proteins 0.000 description 1
- 101001014196 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 1 Proteins 0.000 description 1
- 101001043754 Homo sapiens Inhibitor of nuclear factor kappa-B kinase subunit beta Proteins 0.000 description 1
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 1
- 101000578774 Homo sapiens MAP kinase-activated protein kinase 5 Proteins 0.000 description 1
- 101000687968 Homo sapiens Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Proteins 0.000 description 1
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101000976899 Homo sapiens Mitogen-activated protein kinase 15 Proteins 0.000 description 1
- 101000945090 Homo sapiens Ribosomal protein S6 kinase alpha-3 Proteins 0.000 description 1
- 101000945096 Homo sapiens Ribosomal protein S6 kinase alpha-5 Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000691459 Homo sapiens Serine/threonine-protein kinase N2 Proteins 0.000 description 1
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 1
- 101001001648 Homo sapiens Serine/threonine-protein kinase pim-2 Proteins 0.000 description 1
- 101000922131 Homo sapiens Tyrosine-protein kinase CSK Proteins 0.000 description 1
- 101001047681 Homo sapiens Tyrosine-protein kinase Lck Proteins 0.000 description 1
- 101001117146 Homo sapiens [Pyruvate dehydrogenase (acetyl-transferring)] kinase isozyme 1, mitochondrial Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010052341 Impaired insulin secretion Diseases 0.000 description 1
- 102100021854 Inhibitor of nuclear factor kappa-B kinase subunit beta Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 150000007649 L alpha amino acids Chemical class 0.000 description 1
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-UHFFFAOYSA-N L-methionine sulfone Natural products CS(=O)(=O)CCC(N)C(O)=O UCUNFLYVYCGDHP-UHFFFAOYSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
- DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 102100034069 MAP kinase-activated protein kinase 2 Human genes 0.000 description 1
- 101710141394 MAP kinase-activated protein kinase 2 Proteins 0.000 description 1
- 102100028397 MAP kinase-activated protein kinase 3 Human genes 0.000 description 1
- 101710141393 MAP kinase-activated protein kinase 3 Proteins 0.000 description 1
- 102100028396 MAP kinase-activated protein kinase 5 Human genes 0.000 description 1
- 102100026299 MAP kinase-interacting serine/threonine-protein kinase 1 Human genes 0.000 description 1
- 101710139011 MAP kinase-interacting serine/threonine-protein kinase 1 Proteins 0.000 description 1
- 102100033610 MAP kinase-interacting serine/threonine-protein kinase 2 Human genes 0.000 description 1
- 101710138999 MAP kinase-interacting serine/threonine-protein kinase 2 Proteins 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101150003567 Mapk12 gene Proteins 0.000 description 1
- 101150060694 Mapk13 gene Proteins 0.000 description 1
- 102100024262 Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 108700036166 Mitogen-Activated Protein Kinase 11 Proteins 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 102100026929 Mitogen-activated protein kinase 11 Human genes 0.000 description 1
- 102000056243 Mitogen-activated protein kinase 12 Human genes 0.000 description 1
- 108700015929 Mitogen-activated protein kinase 12 Proteins 0.000 description 1
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 description 1
- 102000056248 Mitogen-activated protein kinase 13 Human genes 0.000 description 1
- 102100023483 Mitogen-activated protein kinase 15 Human genes 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 101100202399 Oryza sativa subsp. japonica SAPK4 gene Proteins 0.000 description 1
- PEMUHKUIQHFMTH-UHFFFAOYSA-N P-Bromo-DL-phenylalanine Chemical compound OC(=O)C(N)CC1=CC=C(Br)C=C1 PEMUHKUIQHFMTH-UHFFFAOYSA-N 0.000 description 1
- 101150020891 PRKCA gene Proteins 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 1
- 101710088493 Rho-associated protein kinase 2 Proteins 0.000 description 1
- 102100033643 Ribosomal protein S6 kinase alpha-3 Human genes 0.000 description 1
- 102100033645 Ribosomal protein S6 kinase alpha-5 Human genes 0.000 description 1
- 101150105578 SAPK3 gene Proteins 0.000 description 1
- 241000143980 Satyrinae Species 0.000 description 1
- 102000015602 Septin Human genes 0.000 description 1
- 108050004875 Septin Proteins 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100026180 Serine/threonine-protein kinase N2 Human genes 0.000 description 1
- 102100036120 Serine/threonine-protein kinase pim-2 Human genes 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 101001045447 Synechocystis sp. (strain PCC 6803 / Kazusa) Sensor histidine kinase Hik2 Proteins 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000005497 Thymidylate Synthase Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 1
- 102100024036 Tyrosine-protein kinase Lck Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 102000052549 Wnt-3 Human genes 0.000 description 1
- 108700020985 Wnt-3 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- DPEDQMJQDPUPBC-UHFFFAOYSA-N [4-methyl-5-[2-(3-methyl-4-morpholin-4-ylanilino)pyrimidin-4-yl]-1,3-thiazol-2-yl]methanol Chemical compound N1=C(CO)SC(C=2N=C(NC=3C=C(C)C(N4CCOCC4)=CC=3)N=CC=2)=C1C DPEDQMJQDPUPBC-UHFFFAOYSA-N 0.000 description 1
- QJSPGFFROFQDPM-UHFFFAOYSA-N [5-[2-(3-methoxy-4-piperidin-1-ylanilino)pyrimidin-4-yl]-4-methyl-1,3-thiazol-2-yl]methanol Chemical compound C=1C=C(N2CCCCC2)C(OC)=CC=1NC(N=1)=NC=CC=1C=1SC(CO)=NC=1C QJSPGFFROFQDPM-UHFFFAOYSA-N 0.000 description 1
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 125000003172 aldehyde group Chemical group 0.000 description 1
- 150000001323 aldoses Chemical class 0.000 description 1
- 150000001335 aliphatic alkanes Chemical group 0.000 description 1
- 150000001336 alkenes Chemical group 0.000 description 1
- 150000001345 alkine derivatives Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940124277 aminobutyric acid Drugs 0.000 description 1
- 229960002684 aminocaproic acid Drugs 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002141 anti-parasite Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003096 antiparasitic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000005441 aurora Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 108010046616 cdc25 Phosphatases Proteins 0.000 description 1
- 102000007588 cdc25 Phosphatases Human genes 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 210000004756 chromatid Anatomy 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- PMMYEEVYMWASQN-IMJSIDKUSA-N cis-4-Hydroxy-L-proline Chemical compound O[C@@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-IMJSIDKUSA-N 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000013044 corticobasal degeneration disease Diseases 0.000 description 1
- 239000002875 cyclin dependent kinase inhibitor Substances 0.000 description 1
- 108010072268 cyclin-dependent kinase-activating kinase Proteins 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000007878 drug screening assay Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000010410 dusting Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- HIJFAJQXOJIHCV-UHFFFAOYSA-N ethyl 4-[4-(diaminomethylideneamino)phenyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C1=CC=C(NC(N)=N)C=C1 HIJFAJQXOJIHCV-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- LTYRAPJYLUPLCI-UHFFFAOYSA-N glycolonitrile Chemical compound OCC#N LTYRAPJYLUPLCI-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- CNUNWZZSUJPAHX-UHFFFAOYSA-N guanidine nitrate Chemical compound NC(N)=N.O[N+]([O-])=O CNUNWZZSUJPAHX-UHFFFAOYSA-N 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 230000006951 hyperphosphorylation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011396 initial chemotherapy Methods 0.000 description 1
- 229910001853 inorganic hydroxide Inorganic materials 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940030980 inova Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000031864 metaphase Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000011806 microball Substances 0.000 description 1
- 230000012312 microtubule nucleation Effects 0.000 description 1
- 101150101778 mik1 gene Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- YGHVKFBSWBCSOE-UHFFFAOYSA-N n-(2-methoxyethyl)-4-[[4-(4-methyl-2-pyridin-3-yl-1,3-thiazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)NCCOC)=CC=C1NC1=NC=CC(C2=C(N=C(S2)C=2C=NC=CC=2)C)=N1 YGHVKFBSWBCSOE-UHFFFAOYSA-N 0.000 description 1
- FBAFPGCLWAAVDY-UHFFFAOYSA-N n-(2-methoxyethyl)-4-nitrobenzenesulfonamide Chemical compound COCCNS(=O)(=O)C1=CC=C([N+]([O-])=O)C=C1 FBAFPGCLWAAVDY-UHFFFAOYSA-N 0.000 description 1
- FIYJCMRTYLITDU-UHFFFAOYSA-N n-[(3-aminophenyl)methyl]benzamide Chemical compound NC1=CC=CC(CNC(=O)C=2C=CC=CC=2)=C1 FIYJCMRTYLITDU-UHFFFAOYSA-N 0.000 description 1
- NWYIGCFVWFBJMA-UHFFFAOYSA-N n-[(3-nitrophenyl)methyl]benzamide Chemical compound [O-][N+](=O)C1=CC=CC(CNC(=O)C=2C=CC=CC=2)=C1 NWYIGCFVWFBJMA-UHFFFAOYSA-N 0.000 description 1
- VDQWPBRATCLFLV-UHFFFAOYSA-N n-[5-[3-(dimethylamino)prop-2-enoyl]-4-methyl-1,3-thiazol-2-yl]-n-ethylacetamide Chemical compound CCN(C(C)=O)C1=NC(C)=C(C(=O)C=CN(C)C)S1 VDQWPBRATCLFLV-UHFFFAOYSA-N 0.000 description 1
- YJDTYCZRWYORMF-UHFFFAOYSA-N n-[[3-(diaminomethylideneamino)phenyl]methyl]benzamide Chemical compound NC(=N)NC1=CC=CC(CNC(=O)C=2C=CC=CC=2)=C1 YJDTYCZRWYORMF-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- VBYYPCNNGNGURO-UHFFFAOYSA-N nitric acid;2-(3-nitrophenyl)guanidine Chemical compound O[N+]([O-])=O.NC(N)=NC1=CC=CC([N+]([O-])=O)=C1 VBYYPCNNGNGURO-UHFFFAOYSA-N 0.000 description 1
- 230000004942 nuclear accumulation Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 230000000269 nucleophilic effect Effects 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000020273 regulation of microtubule cytoskeleton organization Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008261 resistance mechanism Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- CMZUMMUJMWNLFH-UHFFFAOYSA-N sodium metavanadate Chemical compound [Na+].[O-][V](=O)=O CMZUMMUJMWNLFH-UHFFFAOYSA-N 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 230000020347 spindle assembly Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 125000004496 thiazol-5-yl group Chemical group S1C=NC=C1* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 229940045860 white wax Drugs 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 229910000166 zirconium phosphate Inorganic materials 0.000 description 1
- 229930195724 β-lactose Natural products 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Communicable Diseases (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0411791.7A GB0411791D0 (en) | 2004-05-26 | 2004-05-26 | Compounds |
| PCT/GB2005/002134 WO2005116025A2 (en) | 2004-05-26 | 2005-05-26 | 2-substituted-4-heteroaryl-pyrimidines useful for the treatment of proliferative disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06013632A true MXPA06013632A (es) | 2007-03-23 |
Family
ID=32671118
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06013632A MXPA06013632A (es) | 2004-05-26 | 2005-05-26 | 4-heteroaril-pirimidinas 2-sustituidas utiles para el tratamiento de trastornos proliferativos. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20090137572A1 (enExample) |
| EP (1) | EP1756098A2 (enExample) |
| JP (1) | JP5026259B2 (enExample) |
| CN (1) | CN1989138A (enExample) |
| AU (1) | AU2005247682A1 (enExample) |
| BR (1) | BRPI0511616A (enExample) |
| CA (1) | CA2566051A1 (enExample) |
| GB (1) | GB0411791D0 (enExample) |
| IL (1) | IL179508A0 (enExample) |
| MX (1) | MXPA06013632A (enExample) |
| WO (1) | WO2005116025A2 (enExample) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0205690D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205688D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| GB0205693D0 (en) | 2002-03-09 | 2002-04-24 | Astrazeneca Ab | Chemical compounds |
| JP2005524672A (ja) | 2002-03-09 | 2005-08-18 | アストラゼネカ アクチボラグ | Ｃｄｋ阻害活性を有するイミダゾリル置換ピリミジン誘導体 |
| GB0311276D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| GB0311274D0 (en) | 2003-05-16 | 2003-06-18 | Astrazeneca Ab | Chemical compounds |
| MX2007005125A (es) * | 2004-10-28 | 2007-07-04 | Irm Llc | Compuestos y composiciones como moduladores de la senda de hedgehog. |
| CN101203500B (zh) * | 2005-01-25 | 2013-08-21 | 格利尼公司 | 取代的芳胺化合物和它们作为5-ht6调节剂的用途 |
| AU2006209216A1 (en) * | 2005-01-25 | 2006-08-03 | Galenea Corp | Substituted arylamine compounds and their use as 5-HT6 modulators |
| CN101421265A (zh) | 2006-01-18 | 2009-04-29 | 安姆根有限公司 | 作为蛋白激酶b(pkb)抑制剂的噻唑化合物 |
| WO2007132220A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combination of a 2-substituted-4-heter0aryl-pyrimidine amine with a cytotoxic drug and use thereof in the treatment of a proliferative disorder |
| GB0609530D0 (en) * | 2006-05-12 | 2006-06-21 | Cyclacel Ltd | Combination |
| WO2007132221A1 (en) * | 2006-05-12 | 2007-11-22 | Cyclacel Limited | Combined anticancer pyrimidine-thiazole aurora kinase inhibitors |
| WO2009011871A2 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of pkb |
| AU2008276521B2 (en) | 2007-07-17 | 2011-11-03 | Amgen Inc. | Heterocyclic modulators of PKB |
| US20110190280A1 (en) * | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
| WO2009047359A1 (en) * | 2007-10-12 | 2009-04-16 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| WO2009076140A1 (en) * | 2007-12-13 | 2009-06-18 | Smithkline Beecham Corporation | Thiazole and oxazole kinase inhibitors |
| HUE030912T2 (en) | 2008-02-15 | 2017-06-28 | Rigel Pharmaceuticals Inc | Pyrimidine-2-amine compounds and their use as inhibitors of yak kinases |
| GB0805477D0 (en) * | 2008-03-26 | 2008-04-30 | Univ Nottingham | Pyrimidines triazines and their use as pharmaceutical agents |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| EP2440058A4 (en) | 2009-06-12 | 2012-11-21 | Dana Farber Cancer Inst Inc | MELTED HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
| KR20120082906A (ko) | 2009-09-30 | 2012-07-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법 |
| WO2011059610A1 (en) * | 2009-11-10 | 2011-05-19 | Glaxosmithkline Llc | Benzene sulfonamide thiazole and oxazole compounds |
| EP2937345B1 (en) | 2009-12-29 | 2018-03-21 | Dana-Farber Cancer Institute, Inc. | Type ii raf kinase inhibitors |
| WO2012113774A1 (en) * | 2011-02-24 | 2012-08-30 | Nerviano Medical Sciences S.R.L. | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors |
| WO2013059634A1 (en) | 2011-10-20 | 2013-04-25 | The Regents Of The University Of California | Use of cdk9 inhibitors to reduce cartilage degradation |
| WO2013074986A1 (en) * | 2011-11-17 | 2013-05-23 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| US10112927B2 (en) | 2012-10-18 | 2018-10-30 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| US10000483B2 (en) | 2012-10-19 | 2018-06-19 | Dana-Farber Cancer Institute, Inc. | Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2015058140A1 (en) | 2013-10-18 | 2015-04-23 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7) |
| WO2015058126A1 (en) | 2013-10-18 | 2015-04-23 | Syros Pharmaceuticals, Inc. | Heteroaromatic compounds useful for the treatment of prolferative diseases |
| RU2016141934A (ru) | 2014-04-04 | 2018-05-07 | Сирос Фармасьютикалз, Инк. | Ингибиторы циклин-зависимой киназы 7 (cdk7) |
| US10017477B2 (en) | 2014-04-23 | 2018-07-10 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| WO2015164604A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| US10300073B2 (en) | 2014-10-14 | 2019-05-28 | The Regents Of The University Of California | Use of CDK9 and BRD4 inhibitors to inhibit inflammation |
| AU2015371251B2 (en) | 2014-12-23 | 2020-06-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (CDK7) |
| CN107427521B (zh) | 2015-03-27 | 2021-08-03 | 达纳-法伯癌症研究所股份有限公司 | 细胞周期蛋白依赖性激酶的抑制剂 |
| EP3307728A4 (en) | 2015-06-12 | 2019-07-17 | Dana Farber Cancer Institute, Inc. | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND CHINESE INHIBITORS |
| USRE49850E1 (en) * | 2015-08-04 | 2024-02-27 | Aucentra Therapeutics Pty Ltd | N-(pyridin-2-yl)-4-(thiazol-5-yl)pyrimidin-2-amine derivatives as therapeutic compounds |
| JP7028766B2 (ja) | 2015-09-09 | 2022-03-02 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | サイクリン依存性キナーゼの阻害剤 |
| AU2019207517A1 (en) * | 2018-01-15 | 2020-08-27 | Aucentra Therapeutics Pty Ltd | 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| CN111039941B (zh) * | 2018-10-12 | 2023-03-21 | 上海医药集团股份有限公司 | 一种含氮杂环化合物、其制备方法及应用 |
| WO2020140098A1 (en) | 2018-12-28 | 2020-07-02 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| KR20260040130A (ko) * | 2023-06-14 | 2026-03-23 | 프로테나 바이오사이언시즈 리미티드 | 신경계 장애 치료를 위한 5-(신놀린-6-일)티아졸 화합물 |
| CN116903592B (zh) * | 2023-07-13 | 2025-08-01 | 特科罗生物科技(成都)有限公司 | 一种嘧啶胺类nuak抑制剂及其制备方法和用途 |
| WO2026024674A1 (en) | 2024-07-22 | 2026-01-29 | Genesis Therapeutics, Inc. | Methods of treating skp2-associated cancers |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5516775A (en) * | 1992-08-31 | 1996-05-14 | Ciba-Geigy Corporation | Further use of pyrimidine derivatives |
| CA2174080A1 (en) * | 1993-10-12 | 1995-04-20 | Paul Edward Aldrich | 1n-alkyl-n-arylpyrimidinamines and derivatives thereof |
| GB9519275D0 (en) * | 1995-09-21 | 1995-11-22 | Univ Dundee | Substances and their therapeutic use |
| GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
| DE69736351T4 (de) * | 1996-05-08 | 2009-07-23 | Cyclacel Ltd. | Methoden und mittel zur hemmung der cdk4-aktivität |
| US6703395B2 (en) * | 1998-03-04 | 2004-03-09 | Institute Of Experimental Botany Of The Academy Of Sciences Of The Czech Republic | Cyclin dependent kinase inhibitor |
| AU753015B2 (en) * | 1998-03-04 | 2002-10-03 | Cyclacel Limited | Cyclin dependent kinase inhibitor |
| US6417185B1 (en) * | 1998-06-19 | 2002-07-09 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| US7045519B2 (en) * | 1998-06-19 | 2006-05-16 | Chiron Corporation | Inhibitors of glycogen synthase kinase 3 |
| AU2001242629B2 (en) * | 2000-03-29 | 2005-08-11 | Cyclacel Limited | 2-substituted 4-heteroaryl-pyrimidines and their use in the treatment of proliferative disorders |
| GB0107901D0 (en) * | 2001-03-29 | 2001-05-23 | Cyclacel Ltd | Anti-cancer compounds |
| CA2446756C (en) * | 2001-06-01 | 2011-03-08 | Vertex Pharmaceuticals Incorporated | Thiazole compounds useful as inhibitors of protein kinase |
| US20040181066A1 (en) * | 2001-08-01 | 2004-09-16 | Fraley Mark E. | Tyrosine kinase inhibitors |
| ATE349443T1 (de) * | 2001-09-28 | 2007-01-15 | Cyclacel Ltd | N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n- phenylamine als antiproliferative verbindungen |
| GB0226582D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Anti-viral compounds |
| GB0226583D0 (en) * | 2002-11-14 | 2002-12-18 | Cyclacel Ltd | Compounds |
| GB0229581D0 (en) * | 2002-12-19 | 2003-01-22 | Cyclacel Ltd | Use |
| WO2004087698A2 (en) * | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
| EP1648875A1 (en) * | 2003-07-30 | 2006-04-26 | Cyclacel Limited | 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors |
| CA2533870A1 (en) * | 2003-07-30 | 2005-02-10 | Shudong Wang | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors |
| CA2542880A1 (en) * | 2003-10-21 | 2005-05-12 | Cyclacel Limited | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
| WO2005113550A1 (ja) * | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | アミノピリミジン誘導体及びその医薬としての用途 |
-
2004
- 2004-05-26 GB GBGB0411791.7A patent/GB0411791D0/en not_active Ceased
-
2005
- 2005-05-26 CN CNA2005800241399A patent/CN1989138A/zh active Pending
- 2005-05-26 WO PCT/GB2005/002134 patent/WO2005116025A2/en not_active Ceased
- 2005-05-26 EP EP05748147A patent/EP1756098A2/en not_active Withdrawn
- 2005-05-26 JP JP2007514117A patent/JP5026259B2/ja not_active Expired - Fee Related
- 2005-05-26 CA CA002566051A patent/CA2566051A1/en not_active Abandoned
- 2005-05-26 BR BRPI0511616-3A patent/BRPI0511616A/pt not_active IP Right Cessation
- 2005-05-26 US US11/596,740 patent/US20090137572A1/en not_active Abandoned
- 2005-05-26 AU AU2005247682A patent/AU2005247682A1/en not_active Abandoned
- 2005-05-26 MX MXPA06013632A patent/MXPA06013632A/es not_active Application Discontinuation
-
2006
- 2006-11-22 IL IL179508A patent/IL179508A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008500320A (ja) | 2008-01-10 |
| US20090137572A1 (en) | 2009-05-28 |
| GB0411791D0 (en) | 2004-06-30 |
| JP5026259B2 (ja) | 2012-09-12 |
| WO2005116025A3 (en) | 2006-02-23 |
| IL179508A0 (en) | 2007-05-15 |
| AU2005247682A1 (en) | 2005-12-08 |
| BRPI0511616A (pt) | 2008-01-02 |
| CN1989138A (zh) | 2007-06-27 |
| EP1756098A2 (en) | 2007-02-28 |
| WO2005116025A2 (en) | 2005-12-08 |
| CA2566051A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5026259B2 (ja) | 増殖性障害の治療に有用な２−置換−４−ヘテロアリール−ピリミジン | |
| EP1567522B1 (en) | Pyrimidine compounds | |
| US7902361B2 (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy | |
| AU2007314341B2 (en) | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | |
| US7576091B2 (en) | Thiazolo-, oxazalo and imidazolo-quinazoline compounds capable of inhibiting protein kinases | |
| CA2592723A1 (en) | 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy | |
| CA2533870A1 (en) | Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors | |
| US20090215805A1 (en) | 4-Heteroaryl Pyrimidine Derivatives and use thereof as Protein Kinase Inhibitors | |
| CA2554329A1 (en) | Pyridinyl - or pyrimidinyl thiazoles with protein kinase inhibiting activity | |
| WO2009118567A2 (en) | Pyrimidines, triazines and their use as pharmaceutical agents | |
| EP2209779A1 (en) | Heterocyclic urea and thiourea derivatives and methods of use thereof | |
| CN1898237B (zh) | 嘧啶-4-基-3,4-硫酮化合物及其治疗用途 | |
| MX2007000425A (es) | Nuevos derivados de 2,4-diaminotiazol-5-ona. | |
| MXPA06004442A (en) | Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |